Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

Core Viewpoint - Immix Biopharma is advancing its CAR-T therapy NXC-201 for relapsed/refractory AL Amyloidosis, demonstrating a 75% complete response rate in patients with a median of 4 prior lines of therapy, with further data to be presented at the upcoming ASH Annual Meeting [1][2][3]. Company Overview - Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and select immune-mediated diseases [10]. - The lead candidate, NXC-201, is a BCMA-targeted CAR-T cell therapy currently evaluated in two clinical trials: NEXICART-1 (ex-U.S.) and NEXICART-2 (U.S.) [10][7]. Clinical Trials - NEXICART-1 is an open-label Phase 1b/2 trial assessing NXC-201 in patients with relapsed/refractory multiple myeloma and AL Amyloidosis, focusing on safety and efficacy [4]. - NEXICART-2 is a U.S. Phase 1b/2 trial designed to enroll 40 patients with adequate cardiac function, evaluating two doses of NXC-201 [5]. - Initial data from NEXICART-1 indicates no neurotoxicity associated with NXC-201 [6]. Market Insights - The U.S. prevalence of relapsed/refractory AL Amyloidosis is projected to grow at 12% annually, reaching approximately 33,277 patients in 2024 [9]. - The AL Amyloidosis market was valued at $3.6 billion in 2017 and is expected to reach $6 billion by 2025 [9]. Presentation Details - NXC-201 data will be presented at the 66th ASH Annual Meeting in San Diego, California, on December 9, 2024, highlighting its efficacy and safety [3][2].